Evidence map›Paper›PMID 30309213›Full record

ArticleRadiation oncology journal2018

Single nucleotide polymorphism of <italic>GSTP1</italic> and pathological complete response in locally advanced rectal cancer patients treated with neoadjuvant concomitant radiochemotherapy.

Luca Nicosia, Giovanna Gentile, Chiara Reverberi, Giuseppe Minniti, Maurizio Valeriani, Vitaliana de Sanctis, Luca Marinelli, Fabiola Cipolla, Ottavia de Luca, Maurizio Simmaco and 1 more

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Radiation oncology journal, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
0.4field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it, 7 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Disease course of lung oligometastatic colorectal cancer treated with stereotactic body radiotherapy.Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] · 2020
    Article
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 1 country.

Luca NicosiaDepartment of Radiation Oncology, Sant'Andrea Hospital, Sapienza University of Rome, Rome, Italy.
Giovanna GentileDepartment of Neuroscience, Mental Health and Sense Organs, Sapienza University of Rome, Rome, Italy.
Chiara ReverberiDepartment of Radiation Oncology, Sant'Andrea Hospital, Sapienza University of Rome, Rome, Italy.
Giuseppe MinnitiDepartment of Neurological Sciences, IRCCS Neuromed, Pozzilli, Italy.
Maurizio ValerianiDepartment of Radiation Oncology, Sant'Andrea Hospital, Sapienza University of Rome, Rome, Italy.
Vitaliana de SanctisDepartment of Radiation Oncology, Sant'Andrea Hospital, Sapienza University of Rome, Rome, Italy.
Luca MarinelliDepartment of Radiation Oncology, Sant'Andrea Hospital, Sapienza University of Rome, Rome, Italy.
Fabiola CipollaDepartment of Neuroscience, Mental Health and Sense Organs, Sapienza University of Rome, Rome, Italy.
Ottavia de LucaDepartment of Advanced Molecular Diagnostic, Sant'Andrea Hospital, Sapienza University of Rome, Rome, Italy.
Maurizio SimmacoDepartment of Neuroscience, Mental Health and Sense Organs, Sapienza University of Rome, Rome, Italy.
Mattia F OstiDepartment of Radiation Oncology, Sant'Andrea Hospital, Sapienza University of Rome, Rome, Italy.
Sapienza University of Rome · ITCTO Andrea Alesini · ITIstituto Neurologico Mediterraneo · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeStandard treatment for locally advanced rectal cancer consists of neoadjuvant radiochemotherapy with concomitant fluoropyrimidine or oxaliplatin and surgery with curative intent. Pathological complete response has shown to be predictive for better outcome and survival; nevertheless there are no biological or genetic factors predictive for response to treatment. We explored the correlation between the single nucleotide polymorphisms (SNPs) GSTP1 (A313G) and XRCC1 (G28152A), and the pathological complete response and survival after neoadjuvant radiochemotherapy in locally advanced rectal cancer patients. MATERIALS AND

methodsGenotypes GSTP1 (A313G) and XRCC1 (G28152A) were determined by pyrosequencing technology in 80 patients affected by locally advanced rectal cancer.

resultsThe overall rate of pathological complete response in our study population was 18.75%. Patients homozygous AA for GSTP1 (A313G) presented a rate of pathological complete response of 26.6% as compared to 8.5% of the AG+GG population (p = 0.04). The heterozygous comparison (AA vs. AG) showed a significant difference in the rate of pathological complete response (26.6% vs. 6.8%; p = 0.034). GSTP1 AA+AG patients presented a 5- and 8-year cancer-specific survival longer than GSTP1 GG patients (87.7% and 83.3% vs. 44.4% and 44.4%, respectively) (p = 0.014). Overall survival showed only a trend toward significance in favor of the haplotypes GSTP1 AA+AG. No significant correlations were found for XRCC1 (G28152A).

conclusionOur results suggest that GSTP1 (A313G) may predict a higher rate of pathological complete response after neoadjuvant radiochemotherapy and a better outcome, and should be considered in a more extensive analysis with the aim of personalization of radiation treatment.

Indexed as

Genetic markerPrognostic factorRadiochemotherapyRectal cancerSingle nucleotide polymorphismTumor response

Identifiers

PMID30309213
PMCPMC6226144
OpenAlexW2894834617

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.